Aminopyridine Derivative Mesylate Crystallization for Improved Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The compound N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide in its free base form has low solubility and bioavailability, particularly in acidic environments, leading to inconsistent drug absorption and reduced efficacy when administered with antacids.
Innovation Solution
The development of a mesylate salt form of the compound, characterized by specific crystalline form (I), which is prepared through a solvent mixing and crystallization process, enhancing solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the compound is used in free base form, then the compound shows high selective and irreversible EGFR TKI activity against T790M mutation, but the solubility and bioavailability are low particularly in acidic environments
Solution Approach 1:
The patent applies parameter changes by converting the compound from free base form to mesylate salt form, which fundamentally alters the chemical parameters (pKa, solubility characteristics) of the compound. This transformation enables the compound to maintain high pharmacological activity while achieving significantly improved solubility in acidic environments such as gastric fluid, thereby resolving the contradiction between reliability and quantity of substance.
Solution Approach 2:
The patent creates a composite material system by forming a salt compound between the EGFR TKI compound and methanesulfonic acid (mesylate). This composite approach combines the pharmacologically active compound with a suitable counterion to achieve both high biological activity and improved physicochemical properties including solubility and bioavailability, thus resolving the contradiction between pharmacological activity and solubility.
2Ease of operation
If the compound is administered with antacids, then the solubility in acidic environment is reduced, but the bioavailability becomes inconsistent and drug absorption is impaired
Solution Approach 1:
The patent applies preliminary anti-action by pre-modifying the compound into mesylate salt form before administration, which anticipates and counteracts the potential harmful effect of antacid co-administration. The mesylate salt formulation ensures that the compound maintains adequate solubility and bioavailability even when gastric pH is elevated by antacids, thereby preventing the inconsistency in drug absorption that would otherwise occur with free base formulation.
Solution Approach 2:
By changing the chemical form from free base to mesylate salt, the patent fundamentally alters the pH-solubility profile of the compound. This parameter change makes the compound's solubility less sensitive to gastric pH variations caused by antacids, ensuring consistent bioavailability regardless of whether antacids are co-administered, thus resolving the contradiction between administration flexibility and bioavailability reliability.
3Quantity of substance
If a formulation is developed to improve solubility, then the bioavailability may be enhanced, but the manufacturing complexity increases
Solution Approach 1:
The patent achieves improved solubility through a straightforward parameter change - converting the compound to its mesylate salt form. This approach requires only a simple salt formation reaction with methanesulfonic acid, followed by conventional crystallization and isolation techniques. The resulting mesylate salt compound exhibits significantly improved solubility without requiring complex formulation technologies such as nanosuspensions, cyclodextrin complexes, or lipid formulations, thereby resolving the contradiction between solubility enhancement and manufacturing simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mesylate salt exhibits improved stability, solubility, and bioavailability, maintaining effective drug absorption even when co-administered with antacids, and is suitable for large-scale production.
Implementation Method 1
a process for preparing the mesylate salt which comprises: (1) mixing the compound and a single organic solvent or a mixed solvent, followed by adding methanesulfonic acid thereto, to prepare a mixture of the mesylate salt; and (2) adding an organic solvent to the mixture to crystallize the mesylate salt
Data Source
AI summary
The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.